Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Zebrafish myelination: a transparent model for remyelination?
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Thrombotic microangiopathy associated with use of interferon-beta.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
FDA approval announcement for ofatumumab
Complex antibody profiling to predict clinical outcome in childhood ADS.
Pericytes are required for blood-brain barrier integrity during embryogenesis.
Novel MS Drug Offers Good Functional Outcomes
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.

Pages